ASCO 2019: Advancing Cancer Treatment with Precision Therapies

May 31, 2019

More Posts and Webinars

Presentations and publications

Date
Focus
Journal title/Conference
1575795946
December 08, 2019
Avapritinib - SM American Society of Hematology (ASH) Annual Meeting
PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
1573772438
November 14, 2019
Avapritinib - GIST Connective Tissue Oncology Society (CTOS) Annual Meeting
Clinical Response to Avapritinib by RECIST and Choi Criteria in ≥ 4th Line and PDGFRA Exon 18 Gastrointestinal Stromal Tumors (GIST)
1573702237
November 14, 2019
Avapritinib - GIST Connective Tissue Oncology Society (CTOS) Annual Meeting
Avapritinib for the Treatment of GIST: Analysis of Efficacy, Safety, and Patient Management Strategies at the Recommended Phase 2 Dose
1573137683
November 07, 2019
Avapritinib - SM ISPOR Europe
Psychometric Evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF) in patients with Advanced Systemic Mastocytosis
1573137287
November 07, 2019
Avapritinib - SM ISPOR Europe
Psychometric Performance of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF)
1569920764
October 01, 2019
Fisogatinib Cancer Discovery
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma
1569920650
October 01, 2019
Fisogatinib Cancer Discovery
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
1569823542
September 30, 2019
Pralsetinib European Society for Medical Oncology (ESMO) Annual Meeting
Treatment With Pralsetinib (BLU-667), a Potent and Selective RET Inhibitor, Provides Rapid Clearance of ctDNA in Patients With RET-Altered Non-Small Cell Lung Cancer (NSCLC) and Thyroid Cancer
1569155420
September 22, 2019
BLU-782 ASBMR 2019 Annual Meeting
A clinical update on BLU-782, an investigational selective ALK2 inhibitor in development for fibrodysplasia ossificans progressiva (FOP)
1568023113
September 09, 2019
Pralsetinib IASLC World Conference on Lung Cancer
Pralsetinib (BLU-667) demonstrates robust activity in RET-fusion-driven intracranial tumor models
1560579358
June 15, 2019
Avapritinib - SM European Hematology Association (EHA) Annual Meeting
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Induces Complete and Durable Responses in Patients (pts) with Advanced Systemic Mastocytosis (AdvSM)
1559552740
June 03, 2019
Pralsetinib ASCO 2019
Clinical Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients with Advanced RET-Fusion+ Non-small Cell Lung Cancer
1559398538
June 01, 2019
Pralsetinib ASCO 2019
Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients with Advanced RET-altered Thyroid Cancers
1559379949
June 01, 2019
Avapritinib - GIST ASCO 2019
Clinical Activity of Avapritinib in ≥4th Line (4L+) and PDGFRA Exon 18 Gastrointestinal Stromal Tumors (GIST)
1553970136
March 30, 2019
Pralsetinib American Association for Cancer Research (AACR) Annual Meeting
Discovery of BLU-667 for RET-driven cancers
1543789289
December 02, 2018
Avapritinib - SM American Society of Hematology (ASH) Annual Meeting
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM) (oral presentation)
1542320453
November 15, 2018
Avapritinib - GIST Connective Tissue Oncology Society (CTOS) Annual Meeting
Avapritinib is Highly Active and Well-tolerated in Patients With Advanced GIST Driven by a Diverse Variety of Oncogenic Mutations in KIT and PDGFRA (oral presentation)
1540246817
October 22, 2018
Avapritinib - GIST European Society for Medical Oncology (ESMO) Annual Meeting
Correlation of ctDNA and Response in Patients with PDGFRα D842 GIST Treated with Avapritinib (poster presentation)
1540246775
October 22, 2018
Avapritinib - GIST European Society for Medical Oncology (ESMO) Annual Meeting
An Open-label, Randomized, Phase 3 Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Metastatic or Unresectable Gastrointestinal Stromal Tumor (poster presentation)
1538864323
October 06, 2018
Pralsetinib American Thyroid Association (ATA) Annual Meeting
Clinical activity of BLU-667, a highly selective RET inhibitor, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study (oral presentation)
1538432296
October 01, 2018
Avapritinib - GIST Clinical Cancer Research
Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors
1538345823
September 30, 2018
BLU-782 American Society for Bone and Mineral Research (ASBMR) Annual Meeting
BLU-782: A highly selective ALK2 inhibitor, designed specifically to target the cause of fibrodysplasia ossificans progressiva
1538000121
September 26, 2018
Pralsetinib IASLC World Conference on Lung Cancer
Activity of osimertinib and the selective RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement (oral presentation)
1538000089
September 26, 2018
Pralsetinib Cancer Discovery
Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion
1529100833
June 15, 2018
Avapritinib - SM European Hematology Association (EHA) Annual Meeting
Avapritinib (BLU-285), a Selective KIT Inhibitor, is Associated with High Response Rate and Tolerable Safety Profile in Advanced Systemic Mastocytosis: Results of a Phase 1 Study (poster presentation)
1523830394
April 15, 2018
Pralsetinib American Association for Cancer Research (AACR) Annual Meeting
Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in ARROW, a phase 1 study of advanced, RET-altered solid tumors (oral presentation)
1523830353
April 15, 2018
Pralsetinib Cancer Discovery
Precision targeted therapy with BLU-667 for RET-driven cancers
1512943899
December 10, 2017
Avapritinib - SM American Society of Hematology (ASH) Annual Meeting
Clinical activity in a Phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (plenary oral presentation)
1510351812
November 10, 2017
Avapritinib - GIST Connective Tissue Oncology Society (CTOS) Annual Meeting
Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST) (oral presentation)
1509574157
November 01, 2017
Avapritinib Science Translational Medicine
A precision therapy against cancers driven by KIT/PDGFRA mutations
1509314866
October 29, 2017
Pralsetinib Molecular Targets and Cancer Therapeutics (AACR – NCI – EORTC)
BLU-667 is a Potent and Highly Selective RET Inhibitor Being Developed for RET-Driven Cancers
1505685990
September 17, 2017
Fisogatinib International Liver Cancer Association (ILCA) Annual Conference
(Clinical activity Of BLU-554, a potent, highly-selective FGFR4 inhibitor in advanced HCC with FGFR4 pathway activation (oral presentation)
1505081139
September 10, 2017
Fisogatinib European Society for Medical Oncology (ESMO) Annual Meeting
Phase 1 Safety and Clinical Activity of BLU-554 in advanced hepatocellular carcinoma (oral presentation)
1501452295
July 30, 2017
Pralsetinib World Congress on Thyroid Cancer
BLU-667 is a potent and highly selective RET inhibitor in development for RET-driven thyroid cancers
1496700240
June 05, 2017
Avapritinib - GIST American Society of Clinical Oncology (ASCO) Annual Meeting
Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST) (oral presentation)
1491170553
April 02, 2017
Avapritinib - GIST American Association for Cancer Research (AACR) Annual Meeting
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)
1491170447
April 02, 2017
Avapritinib - SM American Association for Cancer Research (AACR) Annual Meeting
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)
1480888795
December 04, 2016
Avapritinib - SM American Society of Hematology (ASH) Annual Meeting
Preliminary Safety and Activity in a Phase 1 study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM) (oral presentation)
1480629552
December 01, 2016
Avapritinib - GIST EORTC – NCI – AACR Molecular Targets and Cancer Therapeutics Symposium
Preliminary safety and activity in a first-in-human Phase 1 study of BLU-285, a potent, highly selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor (GIST) (oral presentation)
1480456639
November 29, 2016
Fisogatinib Molecular Targets and Cancer Therapeutics (EORTC – NCI – AACR)
First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation (poster presentation)
1461016563
April 18, 2016
Pralsetinib American Association for Cancer Research (AACR) Annual Meeting
The development of Potent and Selective RET inhibitors
1430516121
May 01, 2015
Research Journal of Clinical Investigation
Targeting cancer with kinase inhibitors
1426541525
March 16, 2015
Fisogatinib Cancer Discovery
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
1411162202
September 19, 2014
Research Nature Communications
Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes
1410384400
September 10, 2014
Research Nature Communications
The landscape of kinase fusions in cancer